In an increasingly uncertain market, where concentration risk looms large, savvy investors are seeking refuge in quality blue-chip stocks. With about 50% of the market's earnings stemming from the top ...
AbbVie (ABBV) just caught a fresh tailwind after HSBC bumped the stock to a Buy, a move that comes on top of strong quarterly ...
Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful ...
No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading ...
Two leading medical stocks that appear reasonable at current levels are AbbVie (NYSE: ABBV) and Merck (NYSE: MRK). The former ...
Dividend investing rewards patience. The best dividend stocks don’t just pay consistently—they raise payouts year after year, ...
AbbVie (NYSE: ABBV) has the highest share price of any stock on this list, at more than $200 each. But don't let the price ...
Lastly, AbbVie is a fantastic income stock. The company is part of the group of Dividend Kings, corporations that have ...
ASH Annual Meeting and Exposition leaves the oncology community buzzing over a series of late-breaking presentations that experts are calling 'unprecedented.' Major pharmaceutical developers such as ...
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases ...
“We sit in the low 60s in terms of Botox share, and that's a clear leadership position by a large margin in the U.S.,” AbbVie ...
Mark Manfredi brings over two decades of international biopharmaceutical industry leadership and cancer drug discovery success to DISCOFinancing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback